Recent Updates
Recently added Catalysts
IMTX

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

Wednesday, October 4, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+20%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Lead asset
IMA401
Phase 1 · Refractory Cancer

Full Press Release Details

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies.
ShareAdd on Google
Tags: IMTX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 4, 2017

Biotech snapshot

Lead asset
IMA401Phase 1
Refractory Cancer →

Catalyst track record

+20%
best trade around IMTX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for IMTX.

See every catalyst's timing & PoA →